Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

46.64USD
16 Jan 2018
Change (% chg)

$-0.26 (-0.55%)
Prev Close
$46.90
Open
$46.70
Day's High
$47.25
Day's Low
$46.60
Volume
1,682,289
Avg. Vol
1,978,663
52-wk High
$47.25
52-wk Low
$29.44

Latest Key Developments (Source: Significant Developments)

Mylan To Complete $1 Billion Share Repurchase Plan
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mylan Nv ::MYLAN TO COMPLETE $1 BILLION SHARE REPURCHASE PLAN.MYLAN - AS PER AGREEMENT WITH ABBOTT RELATED TO ABBOTT EPD DEAL, ABBOTT NOTIFIED MYLAN IT SOLD REMAINING 20.3 MILLION IN MYLAN SHARES PRIOR TO YEAR-END​.  Full Article

Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Biocon Ltd ::CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS.LIBBS FARMACEUTICA TO COMMERCIALIZE PRODUCT IN BRAZIL UNDER BRAND NAME ZEDORA.  Full Article

Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Mylan Nv ::MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS.MYLAN SAYS U.S. PTAB INSTITUTED IPR PROCEEDINGS ON CLAIMS AGAINST 2 ORANGE BOOK-LISTED PATENTS OWNED BY SANOFI FOR LANTUS 100 UNITS/ML.  Full Article

Mylan Says Teva Has Dismissed Its Pending Litigation Against Co
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Mylan Nv ::MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN.MYLAN NV - TEVA HAS AGREED TO WITHDRAW IRISH EQUIVALENT TO THE PATENTS FROM RECENTLY FILED PROCEEDING IN IRELAND.MYLAN NV - TEVA'S PENDING LITIGATION AGAINST CO IS REGARDING CO'S GLATIRAMER ACETATE INJECTION 40 MG/ML, FIRST GENERIC VERSION OF COPAXONE 40 MG/ML.  Full Article

Mylan And Aspen Announce Launch Of Generic Busulfex Injection
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Mylan Nv ::MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION.MYLAN NV - ‍ANNOUNCED U.S. LAUNCH OF MYLERAN INJECTION, 60 MG/10 ML SINGLE-DOSE VIAL, A GENERIC VERSION OF OTSUKA PHARMACEUTICAL'S BUSULFEX INJECTION​.  Full Article

FDA Approves Mylan's Heparin Sodium Injection
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Mylan Nv ::FDA APPROVAL OF HEPARIN SODIUM INJECTION CONTINUES TO DEMONSTRATE MYLAN'S DEEP EXPERTISE IN DEVELOPING COMPLEX PRODUCTS.SAYS EXPECT TO MAKE HEPARIN PRODUCTS AVAILABLE TO U.S. HOSPITALS IN COMING WEEKS.  Full Article

EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Mylan NV ::EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM.EMA ACCEPTANCE OF TRASTUZUMAB, PEGFILGRASTIM FOLLOWS EARLIER WITHDRAWAL OF APPLICATIONS IN RESPONSE TO AUDIT OF BIOCON'S DRUG PRODUCT FACILITY.  Full Article

Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Theravance Biopharma Inc -:Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease.Theravance Biopharma Inc - ‍NDA is supported by companies' Phase 3 program for revefenacin​.  Full Article

Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)
Saturday, 11 Nov 2017 

Nov 10 (Reuters) - Mylan Nv :Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE).Mylan NV - ‍announced it is voluntarily delisting company's ordinary shares from trading on tel aviv stock exchange​.Mylan NV - ‍ delisting of Mylan's ordinary shares from tase will become effective in three months, on February 12, 2018​.  Full Article

Mylan says received civil investigative demand from AG of state of Missouri
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Mylan Nv ::Says on Aug 29, 2017 received civil investigative demand from attorney general of state of Missouri - SEC Filing‍​.Says civil investigative demand seeks information relating to opioids manufactured, marketed or sold by co from Jan 1, 2010 to present related subject matter.Says on October 10, co, Meda Pharmaceuticals got notice CMA was opening investigation for possible infringement of Competition Act 1998, article 101 of TFEU.Says notice regarding CMA investigation was in respect to alleged agreements related to Nefopam, a product from Meda's portfolio.Says on October 16, CMA issued notice under section 26 of Competition Act 1998 to co, Meda Pharma to provide specified information, specified documents.  Full Article

BRIEF-Tax reform relatively neutral for Mylan-CFO

* SAYS ITS BIOSIMILAR FOR AMGEN'S NEULASTA COULD BE A "MID-YEAR OPPORTUNITY"